Home / Companies / Atea Pharmaceuticals, Inc. / 21 Jun 2024
Atea Pharmaceuticals, Inc.: meeting of 21 Jun 2024
Votes reported on Form N-PX, item by item
180 Form N-PX filers reported votes at the Atea Pharmaceuticals, Inc. meeting of 21 Jun 2024. Their records fall into 3 items below, in ballot order: management items first, then proposals from security holders. Each bar shows how the reporting filers split; it is not the result of the meeting.
foragainstabstain, withhold or otheramber tick: the portion cast against management
Items
DIRECTOR ELECTIONSIssuer
Director elections
2 nominees; 47.4% of reported votes for; 43 filers withheld from or voted against at least one nominee.
270 vote records from 70 filers. 27 of the 70 filers that marked the item either way voted against management.
SECTION 14A SAY-ON-PAY VOTESIssuer
Advisory vote on executive pay (say-on-pay)
270 vote records from 180 filers. 46 of the 173 filers that marked the item either way voted against management. 7 filers reported this item without a management mark.
AUDIT-RELATEDIssuer
Audit-related items (auditor ratification)
135 vote records from 70 filers. 0 of the 70 filers that marked the item either way voted against management.
How the largest families voted
| Family | 1. Directors | 2. Say-on-pay | 3. Auditor |
|---|---|---|---|
| Vanguard | For | For | For |
| BlackRock and iShares | Split or no vote | For | For |
| Fidelity | For | For | For |
| Dimensional | Abstain or withhold * | Against * | For |
| State Street and SPDR | Split or no vote | For | For |
| American Century | Abstain or withhold * | Against * | For |
| Invesco | Split or no vote | Against * | For |
| Equitable | Split or no vote | For | For |
| Charles Schwab | For | Against * | For |
| Nuveen and TIAA | For | For | For |
| ProShares and ProFunds | Abstain or withhold * | For | For |
| John Hancock and Manulife | Abstain or withhold * | For | For |
| Morgan Stanley, Eaton Vance and Calvert | Abstain or withhold * | For | For |
| J.P. Morgan | No report | Against * | No report |
| Goldman Sachs | No report | Against * | No report |
| PGIM and Prudential | No report | Against * | No report |
| Northern Trust and FlexShares | No report | For | No report |
| SEI | For | Against * | For |
| T. Rowe Price | For | For | For |
| Lincoln Financial | Abstain or withhold * | For | For |
| Voya | Abstain or withhold * | For | For |
| Nationwide | Abstain or withhold * | For | For |
| Victory Capital | Abstain or withhold * | For | For |
| Brighthouse Funds | Abstain or withhold * | For | For |
| Guggenheim and Rydex | Abstain or withhold * | For | For |
| Columbia Threadneedle | For | For | For |
| BNY Mellon | No report | For | No report |
| Principal | Abstain or withhold * | For | For |
| Pacific Life funds | Split or no vote | For | For |
| Global X | For | Against * | For |
| Federated Hermes | For | For | For |
| AllianceBernstein | No report | For | No report |
| DWS | Abstain or withhold * | For | For |
| Macquarie and Delaware Funds | Abstain or withhold * | For | For |
| Janus Henderson | No report | For | No report |
| Neuberger Berman | No report | Against * | No report |
* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.
Questions
How did large funds vote at the Atea Pharmaceuticals, Inc. meeting?
180 Form N-PX filers reported votes at the meeting of 21 Jun 2024. On say-on-pay, 46 of 173 voted against management (26.6%). The family table lists each of the largest families item by item.
Is this the meeting result?
No. These are the votes of funds and managers that file Form N-PX, counted by filer and by the shares they reported. The certified result, which includes every shareholder, is reported by Atea Pharmaceuticals, Inc. on Form 8-K.
Why are director elections shown as counts only?
Director records name the nominee. This site does not publish pages or rows about individuals, so for director elections it keeps the number of nominees and the split of votes and discards the wording.
Every meeting on file for Atea Pharmaceuticals, Inc.
Provenance: SEC EDGAR, Form N-PX and N-PX/A filings listing Atea Pharmaceuticals, Inc. with a meeting date within three days of 21 Jun 2024. Proposal titles are the most common wording among filers and are replaced by the SEC category where a wording could name a person. Not verified by the SEC. Filings read through 23 Sep 2026.